Capital Advisors Inc. OK Has $4.45 Million Stake in Eli Lilly and Company $LLY

Capital Advisors Inc. OK lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 13.7% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,825 shares of the company’s stock after selling 922 shares during the period. Capital Advisors Inc. OK’s holdings in Eli Lilly and Company were worth $4,445,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of LLY. GraniteShares Advisors LLC raised its holdings in Eli Lilly and Company by 4.6% in the 3rd quarter. GraniteShares Advisors LLC now owns 3,374 shares of the company’s stock valued at $2,574,000 after buying an additional 148 shares during the last quarter. Rexford Capital Inc. increased its position in Eli Lilly and Company by 6.4% in the 3rd quarter. Rexford Capital Inc. now owns 1,583 shares of the company’s stock valued at $1,208,000 after acquiring an additional 95 shares during the period. Financiere des Professionnels Fonds d investissement inc. acquired a new position in Eli Lilly and Company in the 3rd quarter valued at approximately $960,000. Synergy Asset Management LLC raised its stake in shares of Eli Lilly and Company by 101.9% during the third quarter. Synergy Asset Management LLC now owns 54,245 shares of the company’s stock valued at $42,277,000 after acquiring an additional 27,380 shares during the last quarter. Finally, First City Capital Management Inc. lifted its holdings in shares of Eli Lilly and Company by 1.5% during the third quarter. First City Capital Management Inc. now owns 6,340 shares of the company’s stock worth $4,837,000 after purchasing an additional 96 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Up 0.5%

Shares of Eli Lilly and Company stock opened at $1,079.83 on Monday. The stock’s 50-day moving average is $1,013.16 and its 200 day moving average is $851.29. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,111.99. The firm has a market cap of $1.02 trillion, a price-to-earnings ratio of 52.83, a PEG ratio of 0.78 and a beta of 0.35. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company’s revenue was up 53.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a $1.73 dividend. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 33.86%.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Daiwa Capital Markets set a $1,230.00 target price on Eli Lilly and Company and gave the stock a “buy” rating in a research report on Tuesday, December 16th. BMO Capital Markets set a $1,200.00 price objective on Eli Lilly and Company in a research report on Thursday, December 4th. Wolfe Research lifted their price objective on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 3rd. Cantor Fitzgerald reissued an “overweight” rating on shares of Eli Lilly and Company in a research report on Monday, December 1st. Finally, Zacks Research upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday. Five equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company has an average rating of “Buy” and a consensus price target of $1,155.36.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.